Skip to main content
. Author manuscript; available in PMC: 2018 Oct 10.
Published in final edited form as: JCO Precis Oncol. 2017 Sep 13;2017:10.1200/PO.17.00036. doi: 10.1200/PO.17.00036

Figure 3.

Figure 3

Clinical decisions made for a subset of patients annotated with actionable variant calls. (A) Patients annotated in 2015 through clinician-initiated requests and for treatment planning conferences. The fraction of patients represented by the highest variant call (yellow column) and the corresponding fraction of patients with that call enrolled on a trial (green column). (B) Accrual onto genomically-matched clinical trials based on variant actionability (p=0.00004). (C) A subset of patients annotated in 2015 through a clinician-initiated request and for whom a survey was returned. The fraction of patients represented by the highest variant call (yellow column) and the corresponding fraction of patients with that call enrolled on a trial (green column). Trial enrollment varied significantly by variant actionability (p=0.0007).